Laverdeur, E., Peulen, O., Bellahcene, A., Genbauffe, A., Rademaker, G., & Peiffer, R. (11 June 2026). Identification of the role of myoferlin in pancreatic cancer desmoplasia [Poster presentation]. GIGA day. |
Laverdeur, E., Peulen, O., Bellahcene, A., Rademaker, G., Peiffer, R., & Genbauffe, A. (22 May 2026). Identification of the role of myoferlin in immune regulation in pancreatic cancer [Poster presentation]. EDT. |
Soumoy, L., Genbauffe, A., Sant'Angelo, D., Everaert, M., Mukeba-Harchies, L., Sarry, J.-E., Declèves, A.-E., & Journe, F. (25 August 2025). Therapeutic Potential of Glutaminase Inhibition Targeting Metabolic Adaptations in Resistant Melanomas to Targeted Therapy. International Journal of Molecular Sciences, 26 (17), 8241. doi:10.3390/ijms26178241 |
Genbauffe, A., Soumoy, L., De Le Court, Z., Salamone, C., Mukeba-Harchies, L., Colet, J.-M., & Journe, F. (June 2025). Bufalin Targets Protein Translation and Cell Metabolism to Overcome Therapy Resistance in Melanoma [Poster presentation]. EACR, Lisbon, Portugal. |
Genbauffe, A., Soumoy, L., Mukeba-Harchies, L., Colet, J.-M., & Journe, F. (October 2024). Bufalin inhibits c-MYC/eIF4A loop and B-oxidation enzyme translation, fighting melanoma resistance to targeted therapies [Poster presentation]. BACR, Bruxelles, Belgium. |
Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G., Saussez, S., & Journe, F. (04 January 2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell International, 24 (1), 8. doi:10.1186/s12935-023-03196-y |